Lombard Odier Asset Management (Usa) Corp Cyma Bay Therapeutics, Inc. Transaction History

Lombard Odier Asset Management (Usa) Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$1.25 - $2.02 $181,250 - $292,900	-145,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$6.05 - $13.66 $211,750 - $478,100	-35,000 Reduced 19.44%	145,000 $1.04 Million
Q1 2019 May 15, 2019	SELL	$8.16 - $13.42 $322,279 - $530,022	-39,495 Reduced 17.99%	180,000 $2.39 Million
Q4 2018 Feb 14, 2019	SELL	$6.54 - $11.74 $513,821 - $922,364	-78,566 Reduced 26.36%	219,495 $1.73 Million
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.52 $880,616 - $1.18 Million	-80,939 Reduced 21.36%	298,061 $3.3 Million
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $266,500 - $359,500	-25,000 Reduced 6.19%	379,000 $5.09 Million
Q1 2018 May 15, 2018	SELL	$9.0 - $15.16 $1.06 Million - $1.78 Million	-117,247 Reduced 22.49%	404,000 $5.25 Million
Q4 2017 Feb 13, 2018	SELL	$7.67 - $9.31 $28,785 - $34,940	-3,753 Reduced 0.71%	521,247 $4.8 Million
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $3.12 Million - $4.34 Million	525,000	525,000 $4.23 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Usa) Corp, based on Form 13F filings with the SEC.

Stay updated on Lombard Odier Asset Management (Usa) Corp with notifications on news.